See more : ISPAC 1 LTD. (ISPC.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Avadel Pharmaceuticals plc (AVDL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avadel Pharmaceuticals plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Hitek Global Inc. (HKIT) Income Statement Analysis – Financial Results
- UniTTEC Co.,Ltd (000925.SZ) Income Statement Analysis – Financial Results
- Gudme Raaschou Europæiske Ejendomsaktier (GRIEJD.CO) Income Statement Analysis – Financial Results
- City Chic Collective Limited (CCX.AX) Income Statement Analysis – Financial Results
- Keda Industrial Group Co., Ltd. (600499.SS) Income Statement Analysis – Financial Results
Avadel Pharmaceuticals plc (AVDL)
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 27.96M | 0.00 | 0.00 | 22.33M | 59.22M | 103.27M | 172.74M | 150.25M | 173.21M | 14.78M | 22.44M | 26.10M | 32.60M | 37.09M | 42.12M | 38.62M | 36.65M | 23.02M | 23.60M | 55.41M | 25.17M | 18.41M | 13.09M | 10.90M | 11.04M | 9.52M | 8.10M | 4.90M |
Cost of Revenue | 846.00K | 1.49M | 815.00K | 5.74M | 12.13M | 17.52M | 16.30M | 13.25M | 10.92M | 3.38M | 4.35M | 5.86M | 6.28M | 6.91M | 10.12M | 9.62M | 17.32M | 6.25M | 2.53M | 3.60M | 3.68M | 2.37M | 2.17M | 1.75M | 2.09M | 3.53M | 3.10M | 400.00K |
Gross Profit | 27.12M | -1.49M | -815.00K | 16.59M | 47.09M | 85.75M | 156.44M | 137.00M | 162.29M | 11.39M | 18.09M | 20.24M | 26.32M | 30.18M | 32.00M | 29.00M | 19.33M | 16.77M | 21.07M | 51.81M | 21.49M | 16.03M | 10.92M | 9.15M | 8.95M | 5.99M | 5.00M | 4.50M |
Gross Profit Ratio | 96.97% | 0.00% | 0.00% | 74.29% | 79.52% | 83.04% | 90.56% | 91.18% | 93.69% | 77.10% | 80.62% | 77.55% | 80.72% | 81.36% | 75.98% | 75.09% | 52.75% | 72.85% | 89.30% | 93.50% | 85.39% | 87.11% | 83.45% | 83.95% | 81.10% | 62.90% | 61.73% | 91.84% |
Research & Development | 13.26M | 20.70M | 17.10M | 20.44M | 32.92M | 39.33M | 34.22M | 34.61M | 25.61M | 17.30M | 26.69M | 26.12M | 25.09M | 28.69M | 30.42M | 36.25M | 43.56M | 38.23M | 47.30M | 35.36M | 20.22M | 12.24M | 10.66M | 9.79M | 11.05M | 10.61M | 10.10M | 0.00 |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 151.71M | 74.52M | 68.50M | 32.41M | 30.18M | 100.36M | 58.86M | 44.18M | 21.71M | 15.70M | 13.31M | 14.15M | 10.81M | 11.33M | 13.34M | 12.91M | 16.63M | 17.38M | 14.54M | 7.61M | 5.97M | 4.02M | 3.41M | 3.46M | 3.69M | 3.63M | 3.20M | 12.60M |
Other Expenses | 0.00 | 3.35M | 217.00K | 406.00K | 816.00K | 1.90M | 2.09M | -6.55M | 0.00 | -36.00K | 573.00K | 102.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 164.97M | 95.22M | 85.60M | 53.25M | 63.92M | 146.31M | 96.74M | 92.68M | 59.88M | 44.75M | 39.99M | 40.27M | 35.90M | 40.02M | 43.75M | 49.16M | 60.18M | 55.61M | 61.84M | 42.97M | 26.19M | 16.26M | 14.08M | 25.26M | 15.95M | 15.28M | 14.00M | 13.50M |
Cost & Expenses | 165.81M | 95.22M | 85.60M | 59.00M | 76.04M | 163.82M | 113.04M | 105.93M | 70.81M | 48.13M | 44.34M | 46.13M | 42.18M | 46.93M | 53.87M | 58.78M | 77.50M | 61.86M | 64.37M | 46.58M | 29.87M | 18.63M | 16.24M | 27.01M | 18.04M | 18.81M | 17.10M | 13.90M |
Interest Income | 0.00 | 11.12M | 2.13M | 12.59M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 963.00K | 254.00K | 629.00K | 667.00K | 464.00K | 525.00K | 1.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 9.89M | 12.34M | 9.94M | 12.99M | 12.48M | 10.62M | 1.05M | 963.00K | 6.30M | 9.27M | 4.35M | 118.00K | 73.00K | 24.00K | 100.00K | 18.00K | 16.00K | 35.00K | 68.00K | 45.00K | 29.00K | 49.00K | 52.00K | 51.00K | 0.00 | 95.00K | 0.00 | 100.00K |
Depreciation & Amortization | 1.77M | 1.49M | 815.00K | 1.69M | 2.49M | 7.43M | 4.88M | 14.49M | 13.13M | 14.14M | 3.06M | 3.18M | 3.35M | 4.70M | 5.92M | 7.25M | 6.20M | 5.64M | 4.74M | 2.53M | 1.71M | 1.46M | 1.27M | 1.11M | 1.21M | 1.04M | 700.00K | 900.00K |
EBITDA | -149.13M | -97.60M | -84.78M | -34.97M | -23.61M | -95.15M | 65.89M | 5.73M | 115.54M | -94.74M | -50.03M | -8.36M | -5.16M | -4.05M | -5.42M | -11.30M | -33.22M | -33.20M | -36.03M | 9.34M | -2.99M | 1.24M | -1.89M | -14.99M | -5.79M | -8.25M | -8.30M | -8.10M |
EBITDA Ratio | -533.29% | 0.00% | 0.00% | -141.52% | -24.22% | -51.44% | 37.39% | 39.14% | 66.70% | -123.76% | -95.02% | -139.41% | -30.64% | -28.24% | -27.64% | -29.72% | -93.83% | -142.19% | -175.99% | 20.77% | -12.30% | -6.47% | -14.82% | -137.98% | -53.73% | -85.84% | -111.11% | -179.59% |
Operating Income | -137.85M | -98.56M | -85.55M | -36.66M | -16.83M | -104.93M | 88.30M | -4.97M | 71.45M | -93.86M | -50.03M | -3.49M | -9.58M | -9.84M | -11.75M | -20.16M | -40.85M | -38.84M | -40.77M | 8.84M | -4.70M | -223.00K | -3.16M | -16.11M | -7.00M | -9.29M | -9.00M | -9.00M |
Operating Income Ratio | -492.97% | 0.00% | 0.00% | -164.15% | -28.42% | -101.60% | 51.12% | -3.30% | 41.25% | -635.24% | -222.93% | -13.36% | -29.40% | -26.53% | -27.90% | -52.20% | -111.44% | -168.71% | -172.76% | 15.94% | -18.67% | -1.21% | -24.11% | -147.74% | -63.41% | -97.57% | -111.11% | -183.67% |
Total Other Income/Expenses | -22.93M | -12.88M | -7.60M | -10.90M | -14.47M | -8.27M | 3.16M | -4.75M | 6.26M | 3.33M | -4.06M | 1.98M | 1.00M | 1.07M | 314.00K | 1.60M | 1.42M | 1.52M | 9.11M | 463.00K | 272.00K | 2.68M | 295.00K | 11.27M | 322.00K | 232.00K | 800.00K | 600.00K |
Income Before Tax | -160.78M | -111.44M | -93.15M | -5.08M | -38.58M | -113.20M | 91.47M | -9.72M | 78.39M | -90.33M | -54.10M | -7.93M | -8.58M | -8.77M | -11.44M | -18.56M | -39.43M | -37.32M | -31.66M | 9.30M | -4.00M | 2.45M | -2.86M | -4.83M | -6.68M | -9.06M | -8.20M | -8.40M |
Income Before Tax Ratio | -574.96% | 0.00% | 0.00% | -22.75% | -65.16% | -109.61% | 52.95% | -6.47% | 45.26% | -611.38% | -241.03% | -30.38% | -26.33% | -23.63% | -27.16% | -48.06% | -107.58% | -162.12% | -134.18% | 16.78% | -15.88% | 13.32% | -21.85% | -44.34% | -60.49% | -95.14% | -101.23% | -171.43% |
Income Tax Expense | -501.00K | 26.03M | -15.82M | -12.11M | -5.36M | -17.89M | 24.22M | 31.56M | 37.74M | -1.41M | -11.17M | -4.70M | 192.00K | 209.00K | -6.23M | -6.48M | -1.69M | -2.12M | -4.29M | -3.20M | -503.00K | -553.00K | 14.00K | 50.00K | 16.00K | -1.25M | -1.40M | -1.50M |
Net Income | -160.28M | -137.46M | -77.33M | 7.03M | -33.23M | -95.30M | 67.25M | -41.28M | 40.66M | -84.91M | -42.93M | -3.23M | -8.77M | -8.98M | -11.44M | -12.08M | -37.74M | -35.20M | -27.38M | 12.50M | -3.49M | 3.01M | -2.87M | -9.46M | -6.69M | -7.81M | -6.80M | -6.90M |
Net Income Ratio | -573.17% | 0.00% | 0.00% | 31.47% | -56.11% | -92.29% | 38.93% | -27.47% | 23.47% | -574.66% | -191.26% | -12.37% | -26.91% | -24.20% | -27.16% | -31.29% | -102.95% | -152.91% | -116.01% | 22.56% | -13.88% | 16.33% | -21.96% | -86.78% | -60.63% | -82.04% | -83.95% | -140.82% |
EPS | -2.00 | -2.29 | -1.32 | 0.13 | -0.89 | -2.55 | 1.66 | -1.00 | 1.00 | -2.34 | -1.69 | -0.13 | -0.36 | -0.37 | -0.47 | -0.50 | -1.57 | -1.48 | -1.19 | 0.58 | -0.20 | 0.19 | -0.18 | -0.62 | -0.52 | -0.65 | -0.65 | -0.80 |
EPS Diluted | -2.00 | -2.29 | -1.32 | 0.13 | -0.89 | -2.55 | 1.61 | -1.00 | 0.93 | -2.34 | -1.69 | -0.13 | -0.36 | -0.37 | -0.47 | -0.50 | -1.57 | -1.48 | -1.19 | 0.53 | -0.20 | 0.18 | -0.18 | -0.62 | -0.52 | -0.65 | -0.65 | -0.80 |
Weighted Avg Shares Out | 80.17M | 60.09M | 58.54M | 53.00M | 37.40M | 37.33M | 40.47M | 41.25M | 40.58M | 36.21M | 25.41M | 24.95M | 24.67M | 24.41M | 24.23M | 24.08M | 24.02M | 23.81M | 23.00M | 21.51M | 17.76M | 16.20M | 16.20M | 15.33M | 12.94M | 12.05M | 10.46M | 8.63M |
Weighted Avg Shares Out (Dil) | 80.17M | 60.09M | 58.54M | 54.94M | 37.40M | 37.33M | 41.77M | 41.25M | 43.62M | 36.21M | 25.45M | 25.09M | 24.67M | 24.41M | 24.23M | 24.08M | 24.02M | 23.81M | 23.00M | 23.56M | 17.76M | 16.71M | 16.20M | 15.33M | 12.94M | 12.05M | 10.46M | 8.63M |
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023
Avadel Pharmaceuticals to Present at the Jefferies Biotech CNS/Neuro Summit
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Avadel Pharmaceuticals: A Resilient Buy; A Comprehensive Assessment Of Potential Prospects
Avadel Pharmaceuticals plc (AVDL) Q2 2023 Earnings Call Transcript
Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Avadel Pharmaceuticals: Winning Is Sweet
Source: https://incomestatements.info
Category: Stock Reports